OncoCyte Corporation (OCX)

Market Cap	91.80M
Revenue (ttm)	1.88M
Net Income (ttm)	-60.93M
Shares Out	28.60M
EPS (ttm)	-4.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36,670
Open	3.250
Previous Close	3.220
Day's Range	3.110 - 3.340
52-Week Range	1.922 - 4.750
Beta	0.79
Analysts	Strong Buy
Price Target	4.56 (+42.06%)
Earnings Date	Mar 24, 2025

About OCX

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 49
• Stock Exchange: NASDAQ
• Ticker Symbol: OCX
• Website: https://www.oncocyte.com

Financial Performance

In 2024, OncoCyte's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Analyst Forecast

According to 4 analysts, the average rating for OCX stock is "Strong Buy." The 12-month stock price forecast is $4.56, which is an increase of 42.06% from the latest price.

Price Target

$4.56

(42.06% upside)

Analyst Consensus: Strong Buy